✦ LIBER ✦

Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2

✍ Scribed by Jhabvala-Romero, Farida; Evans, Adam; Guo, Shuhua; Denton, Michael; Clinton, Gail Mary

Book ID: 110067997
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 282 KB
Volume: 22
Category: Article
ISSN: 0950-9232
DOI: 10.1038/sj.onc.1206912

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Farnesoid X receptor inhibits tamoxifen-

Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression

✍ Giordano, C; Catalano, S; Panza, S; Vizza, D; Barone, I; Bonofiglio, D; Gelsomin 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 754 KB

Ansamycin antibiotics inhibit Akt activa

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2

✍ Basso, Andrea D; Solit, David B; Munster, Pamela N; Rosen, Neal 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 280 KB

Adenovirus-mediated ribozyme targeting o

Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells

✍ Suzuki, T; Anderegg, B; Ohkawa, T; Irie, A; Engebraaten, O; Halks-Miller, M; Hol 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 200 KB

Anti-HER-3 MAbs inhibit HER-3-mediated s

Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies

✍ Edward Htun van der Horst; Marta Murgia; Martin Treder; Axel Ullrich 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 386 KB

## Abstract Two members of the EGF receptor family, HER2 and HER3, act as key oncogenes in breast cancer cells. A MAb against HER2, trastuzumab, interferes with HER2 signaling and istherapeutically effective in humans. Here, we explored the biologic effects of an antibody against HER3 (α‐HER3^ECD^)

Combined effects of lapatinib and bortez

Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells

✍ Chuandong Ma; Xiuqing Niu; Jianmin Luo; Zhimin Shao; Kunwei Shen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 546 KB

Genistein sensitizes inhibitory effect o

Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells

✍ Zhiming Mai; George L. Blackburn; Jin-Rong Zhou 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

## Abstract Although tamoxifen (TAM) is used for the front‐line treatment and prevention of estrogen receptor‐positive (ER+) breast tumors, nearly 40% of estrogen‐dependent breast tumors do not respond to TAM treatment. Moreover, the positive response is usually of short duration, and most tumors e